Nuvation Bio (NUVB) Stock Price, News & Analysis

Company Overview

Nuvation Bio Inc. is a biopharmaceutical company focused on discovering and developing medicines for patients with cancer. The company applies drug discovery, translational research and clinical development capabilities to pursue therapies for cancers with significant unmet medical needs.

Nuvation Bio’s pipeline has included investigational small-molecule oncology therapies, including NUV-422, a cyclin-dependent kinase inhibitor designed to target pathways involved in cancer cell growth. As with the company’s other development programs, these candidates remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established for general use.

Founded in 2018, Nuvation Bio is based in the United States and conducts research and development intended to support the potential global treatment of cancer. The company was founded and is led by David Hung, M.D., a biotech executive and physician who previously founded Medivation.

Key Stats

• Today's Range: $5.67 to $5.83
• 50-Day Range: $5.70 to $7.25
• 52-Week Range: $2.99 to $9.75
• Volume: 2.82 million shs
• Average Volume: 4.54 million shs
• Market Capitalization: $2.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Moderate Buy

Nuvation Bio Stock Analysis - MarketRank™

Nuvation Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 651st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvation Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Nuvation Bio has a consensus price target of $13.00, representing about 126.3% upside from its current price of $5.75.

Amount of Analyst Coverage

Nuvation Bio has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuvation Bio are expected to grow in the coming year, from ($0.34) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvation Bio is -13.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvation Bio is -13.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvation Bio has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.71% of the float of Nuvation Bio has been sold short.

Short Interest Ratio / Days to Cover

Nuvation Bio has a short interest ratio ("days to cover") of 10.89, which indicates bearish sentiment.

Change versus previous month

Short interest in Nuvation Bio has recently increased by 7.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvation Bio does not currently pay a dividend.

Dividend Growth

Nuvation Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 14 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,000.00 in company stock.

Percentage Held by Insiders

30.11% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:NUVB
• CIK: 1811063
• Web: www.nuvationbio.com
• Phone: 332-208-6102
• Fax: N/A
• Employees: 305
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Nuvation Bio: $13.00
• High Price Target: $21.00
• Low Price Target: $7.00
• Potential Upside/Downside: +126.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$204.63 million
• Net Margins: -88.18%
• Pretax Margin: -88.18%
• Return on Equity: -46.59%
• Return on Assets: -22.01%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 8.37
• Quick Ratio: 8.14

Sales & Book Value

• Annual Sales: $62.90 million
• Price / Sales: 32.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 6.53

Miscellaneous

• Outstanding Shares: 351,120,000
• Free Float: 245,400,000
• Market Cap: $2.02 billion
• Optionable: Optionable
• Beta: 1.52